Roche Group entered into a strategic license collaboration with a leading cell therapy-focused venture targeting cancer, as Roche’s Genentech inked a deal with Adaptimmune Therapeutics. Genentech licensed the cell therapy in a bid to develop and commercialize allogeneic cell therapies to treat multiple oncology indications. Roche will pay Adaptimmune upfront $150 million and additional payments of $150 million over five years unless the agreement is terminated earlier. Should the partners progress through the entire clinical development process and produce a commercial winner, Adaptimmune is eligible for payments of up to $3 billion. Roche (Genentech) sees considerable synergy between the formers’ deep expertise in developing and commercializing personalized treatment and Adaptimmune’s allogeneic platform.
TrialSite InvestorWatch provides a brief breakdown of this biotech licensing deal.
What’s Adaptimmune’s background?
Founded in 2008, the UK and Philadelphia-based biotech positions itself as a leading T-cell therapy, focusing on the development of its proprietary SPEAR T-cell receptor platform to treat solid tumors. The company believes this technology has the pote...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).